Edition:
United States

Profile: Allergan plc (AGN)

AGN on New York Consolidated

194.30USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$194.30
Open
--
Day's High
--
Day's Low
--
Volume
15
Avg. Vol
4,220,278
52-wk High
$322.68
52-wk Low
$184.50

Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company's segments are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States.

The Company has global rights to RST-001, a gene therapy approach for the potential treatment of retinitis pigmentosa (RP). The RST-001 optogenetic approach includes a photosensitivity gene, channelrhodopsin-2, to create new photosensors in retinal ganglion cells to restore vision in retinal degenerative conditions. The RST-001 is in Phase I/IIa clinical trials. It has global rights to AKN-083, a preclinical farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH). The Company has global rights for the development programs for the treatment of the multi-factorial elements of NASH, including inflammation, metabolic syndromes and fibrosis. The Company is developing Cenicriviroc (CVC), an oral C-C chemokine receptor type 2 and type 5 (CCR2/5) inhibitor, impacting inflammation and fibrosis, and Evogliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in Phase I study as a treatment for NASH in combination with CVC impacting metabolic element of disease.

In the Company's US Brands, US Medical Aesthetics and International Brands operations, it sells brand pharmaceutical products to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies and managed healthcare providers, such as health maintenance organizations and other institutions. The Company is developing a range of branded products, some of which utilize drug delivery systems, through a combination of internal and collaborative programs, including Restasis MDPF, XEN45, Sarecycline, Esmya, Bimatoprost SR, Tavilermide, Relamorelin, Ubrogepant, Abicipar and Rapastinel. The Company's portfolio of branded pharmaceutical products within the US Brands segment includes Alphagan/Combigan, which is used for the treatment of selective alpha2 agonist; Asacol/Delzicol, which is used for the treatment of ulcerative colitis; Botox, which is used for the treatment of acetylcholine release inhibitor; Bystolic, which is used for the treatment of hypertension; Carafate/Sulcrate, which is used for the treatment of ulcerative colitis; Dalvance, which is used for the treatment of acute bacterial skin infections; Estrace Cream, which is used in hormone therapy; Linzess/Constella, which is used for the treatment of irritable bowel syndrome; Lo Loestrin Fe, which is an oral contraceptive; Lumigan/Ganfort, which is a prostaglandin analogue; Minastrin 24 Fe, which is an oral contraceptive; Namenda XR and Namzaric, which are used for the treatment of dementia; Restasis, which is a topical immunomodulator; Saphris, which is used for the treatment of schizophrenia and bipolar mania; Teflaro, which is used for the treatment of acute bacterial skin infections and community-acquired bacterial pneumonia; Viberzi, which is used for the treatment of irritable bowel syndrome; Viibryd/Fetzima, which is used for the treatment of depressive disorders, and Zenpep, which is used for the treatment of exocrine pancreatic insufficiency.

The US Medical Aesthetics segment offers a range of silicone gel and saline breast implant options, as well as a science-based facial aesthetic portfolio. Its portfolio of products within the US Medical Aesthetics segment includes Aczone, which is used for the treatment of acne; Botox, which is used as musculoskeletal agent; breast implants, which are used in reconstructive plastic surgery, and Juvederm/Voluma, which is used for the treatment of nasolabial folds. The Company's International Brands segment offers a range of branded and aesthetics products outside of the United States. Its portfolio of products within the International Brands segment includes Alphagan/Combigan, breast implants, Botox, Juvederm/Voluma and Lumigan/Ganfort.

The Company competes with McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc.

Company Address

Allergan plc

Clonshaugh Business And Technolo
Coolock
DUBLIN     D17 E400
P: +35321.65235000

Company Web Links